KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash & Equivalents (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Cash & Equivalents for 13 consecutive years, with $93.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 58.94% year-over-year to $93.0 million, compared with a TTM value of $93.0 million through Dec 2025, up 58.94%, and an annual FY2025 reading of $93.0 million, up 58.94% over the prior year.
  • Cash & Equivalents was $93.0 million for Q4 2025 at Travere Therapeutics, down from $110.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $256.6 million in Q1 2022 and bottomed at $32.3 million in Q2 2024.
  • Average Cash & Equivalents over 5 years is $97.1 million, with a median of $68.5 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents crashed 74.76% in 2024, then surged 204.68% in 2025.
  • Year by year, Cash & Equivalents stood at $165.8 million in 2021, then crashed by 62.78% to $61.7 million in 2022, then decreased by 5.69% to $58.2 million in 2023, then rose by 0.62% to $58.5 million in 2024, then soared by 58.94% to $93.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for TVTX at $93.0 million in Q4 2025, $110.9 million in Q3 2025, and $75.2 million in Q2 2025.